Vistagen Therapeutics VTGN
NASDAQ VTGN
$0.31 +0.01 (+3.33%)
At close: Sep 30, 2026 · 4:00 PM EDT

Vistagen Therapeutics (VTGN) EBITDA Margin (2011 - 2026)

Updated

Vistagen Therapeutics' EBITDA Margin came in at -900.81% for fiscal Q1 2027 (quarter ended Jun 30, 2026), up 5559.84 percentage points from -6460.66% a year earlier and up 2683.06 percentage points from the prior quarter.

Analysis

Vistagen Therapeutics (VTGN) EBITDA Margin (2011 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Vistagen Therapeutics reported EBITDA Margin of -2775.90%, up 6433.08 percentage points year-over-year; for FY2026 (ended Mar 31, 2026), it was -5668.01%, up 5818.21 percentage points from FY2025.

  • EBITDA Margin carries a five-year change of -4032.74 percentage points (FY2021 to FY2026).
  • Going back by fiscal year, EBITDA Margin was -11486.21% in FY2025 (-8394.67 pp), -3091.54% in FY2024 (+22960.44 pp) and -26051.98% in FY2023.
  • The fiscal Q1 2027 figure represents the highest quarterly EBITDA Margin since fiscal Q3 2017.
  • Year-over-year, EBITDA Margin increased in four of the last six quarters, with an average year-over-year change of +579.30 percentage points.
  • The fastest year-over-year change in EBITDA Margin over five years came in fiscal Q1 2026 (a gain of 7940.53 percentage points), and the weakest in fiscal Q1 2025 (a drop of 10918.19 percentage points).
  • Business Quant data shows VTGN's EBITDA Margin at -3583.87% (Q4 2026), -6433.00% (Q3 2026) and -7751.94% (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 35.95%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 49.01%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 6.02%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 33.11%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 46.01%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -124.26%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 39.10%
10 Vistagen Therapeutics 13.76 Mn 13.76 Mn - -900.81%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -900.81%
Mar 31, 2026 -3,583.87%
Dec 31, 2025 -6,433.00%
Sep 30, 2025 -7,751.94%
Jun 30, 2025 -6,460.66%
Dec 31, 2024 -6,444.87%
Sep 30, 2024 -7,754.10%
Jun 30, 2024 -14,401.19%
Mar 31, 2024 -6,906.10%
Dec 31, 2023 -1,910.71%
Sep 30, 2023 -2,249.67%
Jun 30, 2023 -3,483.00%
Mar 31, 2023 -6,934.77%
Dec 31, 2022 -5,408.83%
Sep 30, 2022 -1,954.76%
Jun 30, 2022 -6,365.95%
Dec 31, 2021 -2,931.65%
Sep 30, 2021 -3,565.17%
Jun 30, 2021 -2,178.67%
Mar 31, 2021 -1,397.90%
API Access

Vistagen Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=VTGN&period=max&api_key=YOUR_API_KEY